ProPhase Labs, Inc. provided an update regarding its progress and development strategy for Linebacker-1 (LB-1). Linebacker is a small molecule, multi-kinase inhibitor that is being developed by the Company's wholly owned subsidiary, ProPhase BioPharma, Inc. ("PBIO"), as a potential mono-therapy and co-therapy option for hard-to-treat cancers. Originally viewed as a co-therapy, the pre-clinical data generated has given PBIO reason to believe that LB-1 will also be very effective as a mono-therapy.

In First Quarter of 2023, ProPhase collaborated with Eurofins, a globally recognized leading drug discovery company, to execute an in-depth analysis (KINOMEscan(TM) Profiling Service) of Linebacker-1 to determine how many cancer-relevant kinases were affected by Linebacker-1 out of a possible 468 enzymes. ProPhase was excited to learn that numerous critically important kinase targets were inhibited more than 99%. Some of the most inhibited pathways are those well known to promote tumorigenesis, such as the phosphoinositide 3-kinase family (e.g., PIKfyive, PIP5k1 and 2) and the mitogen- activated protein kinase family (e.g.g., MEK3, 4, and 5).

Importantly, the Eurofins analysis revealed several unique targets affected by Linebacker-1 that cancer research organizations highlight as critically important, for which no other pharmaceutical company has developed drugs to treat. The unique interplay of Linebacker with multiple cancer-dependent pathways will be a true differentiator within current treatment paradigms. In line with these impressive results, Linebacker-1 has demonstrated strong preclinical potential in a number of difficult diseases, including tough-to-treat lung and gastric cancers. As development continues, the company intend to position Linebacker-1 as a potential new option for cancer patients suffering from a current lack of quality treatment options.